IBA has signed a contract with the University of Texas MD Anderson Cancer Center to supply three ProteusONE systems for a major upgrade of its Proton Therapy Center in Houston.

The Louvain-la-Neuve, Belgium-based company said the agreement follows a competitive bidding process and includes a full retrofit of the facility, which first opened in 2006. The upgrade will replace existing systems with compact ProteusONE units, designed to deliver intensity-modulated proton therapy in a smaller footprint.

Each system, which includes a multiyear maintenance contract, typically ranges from $45 million to $55 million, according to IBA.
In a statement, IBA CEO Olivier Legrain said, “Being selected by the world’s leading oncology center is a strong validation of IBA’s technology, innovation roadmap, and long-term commitment to proton therapy.”

The announcement comes just weeks after MD Anderson published a phase 3 clinical trial in The Lancet showing that intensity-modulated proton therapy reduced toxicity and improved survival for patients with advanced oropharyngeal cancer, compared to intensity-modulated radiation therapy (IMRT). The study's results are expected to influence future standards of care for this patient group.

IBA said the contract was signed in late December and will be included in its 2025 order intake once the first payment is received.

Founded in Belgium, IBA specializes in particle accelerator systems for medical and industrial applications, with a primary focus on proton therapy. The company employs around 2,000 people globally and is listed on Euronext.

MD Anderson is based in Houston and operates as part of the University of Texas system. It is frequently ranked among the top cancer treatment centers in the United States.

U.S. Healthcare Homepage